Efficacy of anti-LT agents in the treatment of chronic asthma

Anti-LT agents are the first new class of asthma medication to be approved in the last 20 yr. Current asthma treatment guidelines recommend antileukobriene agents as anti-inflammatory therapy for patients with mild, persistent asthma. The role that these drugs will play in clinical practice will bec...

Full description

Saved in:
Bibliographic Details
Published in:Clinical reviews in allergy & immunology 1999, Vol.17 (1-2), p.235-246
Main Author: Spector, S L
Format: Article
Language:English
Subjects:
Asthma
Asthma - drug therapy
Chronic Disease
Clinical medicine
Clinical Trials as Topic
Drug therapy
Humans
Leukotriene Antagonists - therapeutic use
Practice Guidelines as Topic
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-LT agents are the first new class of asthma medication to be approved in the last 20 yr. Current asthma treatment guidelines recommend antileukobriene agents as anti-inflammatory therapy for patients with mild, persistent asthma. The role that these drugs will play in clinical practice will become more apparent as additional experience is gained in their use. The results of clinical studies illustrate their potential: anti-LT agents reduce asthma symptoms, improve airway function, and decrease the need for concomitant beta 2-agonists and inhaled corticosteroids; the incidence of asthma exacerbations may also be reduced. Finally, because these agents are administered orally, they offer the potential for improved patient compliance relative to the more complicated forms of drug administration.
ISSN:1080-0549
1559-0267
DOI:10.1007/BF02737607